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Abstract
Objective: The aim of this study was to analyze the clinical profiles and outcomes of pediatric brainstem 
gliomas treated at our institute. Methodology: We reviewed the files of 18 pediatric age group patients 
diagnosed with brainstem glioma at our institution. The following variables were recorded: age, sex, 
duration of symptoms, date of diagnosis, main clinical symptoms, Karnofsky performance status score, 
magnetic resonance imaging findings, histopathology findings, details of the treatment given, disease 
progression, and date of mortality/last follow‑up. This data were then transferred to SPSS version 23 
which was used for further analysis. Results: The mean age of our cohort was 8.6 years (range 3–15). 
There were 11 (61.1%) males and 7 (38.9%) females. There were 16 (88.9%) patients with diffuse 
intrinsic pontine gliomas (DIPGs), 1 (5.6%) patients with exophytic medullary gliomas, and 1 (5.6%) 
patient with midbrain/tectal glioma. Mean overall survival (OS) was 9.7 months. Mean progression‑free 
survival (PFS) was 6.3 months. All patients with DIPG eventually passed away from their disease. 
Patients with DIPG who received radiotherapy had a longer OS and PFS than those who did not 
(9.8 and 6 months vs. 3.4 and 2.4 months). Diagnostic latency >1 month was found to have a statistically 
significant longer progression‑free interval. Conclusion: DIPGs in the pediatric population have a poor 
prognosis. Radiotherapy serves to increase survival time but is not curative.
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Introduction
Brainstem glioma is a primary 
brainstem neoplasm of glial origin. The 
majority – about 80% of these tumors 
comprise a highly malignant tumor of 
the pons.[1,2] The balance is made up by 
low‑grade gliomas arising elsewhere in the 
brainstem.[3]
Brainstem gliomas have a high incidence 
in children – accounting for 10%–20% of 
all childhood primary brain tumors.[1,3‑9] It 
is estimated that between 2007 and 2011, 
around 350–400 pediatric cases (3/100,000 
pediatric population) were diagnosed yearly 
in the USA.[8] In comparison, brainstem 
gliomas are rarer in the adult population 
accounting for only 1%–2% of all adult 
primary brain tumors.[10‑13]
Tumor behavior and patient clinical course 
differ according to brainstem localization.[3] 
Brainstem gliomas are, therefore, classified 
according to their anatomic location 
and appearance on magnetic resonance 
imaging (MRI) T1 and T2 films.[8] In the 
pediatric age group, they may be stratified 
into three main categories, namely diffuse 
intrinsic pontine glioma (DIPG), exophytic 
medullary glioma, and midbrain or tectal 
glioma.[3,6,13] This is, in contrast to gliomas 
of other locations where tumors are 
categorized based on their histological 
features according to the World Health 
Organization (WHO).
The literature on brainstem gliomas is 
scanty from our part of the globe. To the 
best of our efforts, we were only able to 
access four studies that provided some basic 
rudimentary data on brainstem gliomas 
from our region.[14‑17] Clinical profiles and 
management were not commented on in 
these studies. Thus, keeping in mind the 
scarcity of literature published on our 
population, we conducted this retrospective 
review at our institution to analyze the 
clinical, prognostic, and therapeutic factors 
involved in the management of brainstem 
gliomas. To the best of our knowledge, 
this is the first time such a retrospective 
analysis and review is coming to light from 
our region.
Methodology
We did a retrospective review of all 
pediatric patients diagnosed with brainstem 
glioma at the Aga Khan University Hospital 
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between January 2012 and December 2016 after obtaining 
approval from the Institution’s Ethical Review Committee.
Inclusion criteria
We designed an inclusion criterion as follows: all pediatric 
age group patients (0–18 years of age), in whom the center 
of the tumor bulk, i.e., the epicenter of the tumor resided in 
the brainstem (medulla oblongata, pons, and midbrain) were 
included. The diagnosis was based on the histopathological 
confirmation or a suggestive clinical history supplemented 
by characteristic MRI findings. Patients who refused to be 
a part of the study were excluded from our study sample. 
Furthermore, excluded were all patients with incomplete 
medical records.
Data collection
We reviewed files of patients that met our inclusion criteria 
and collected the following data: patient age, sex, duration 
of symptoms (described as the time between initiation of 
symptoms to first contact with a health‑care provider), 
date of diagnosis, main clinical symptoms, Karnofsky 
performance status (KPS) score, MRI findings (T1‑ and 
T2‑weighted images in at least two planes before and after 
gadolinium contrast enhancement), histopathology in cases 
where a biopsy was done, details of any radiotherapy given, 
details of any chemotherapy given, details of any surgery 
done, clinical or radiological disease progression, date of 
said so progression, and date of mortality/last follow‑up.
All data collected were entered and edited manually onto 
a Microsoft Excel sheet. This was then transferred to the 
Statistical Package for the Social Sciences Software (SPSS 
v.23.0, IBM Corp, USA) which was used for further 
analysis.
Statistical analysis
The data obtained were analyzed at two levels: descriptive 
and analytical. Frequencies, percentages, means, and 
medians were used to describe the characteristics of the 
study participants.
Overall survival (OS) was the time in months from 
diagnosis to death or last follow‑up. Survival was estimated 
using the Kaplan–Meier method. Survival differences 
between variables were compared using the Log‑rank test.
Progression‑free survival (PFS) was the time in months 
from diagnosis to disease progression, either clinically or 
radiologically. It was analyzed the same way as OS.
Results
Patient demographics and presenting features
Based on the inclusion criteria, we mentioned previously, 
the study sample consisted of 18 patients. The mean age of 
our cohort was 8.6 years (range 3–15), with the majority of 
patients being male (61.1%) [Table 1].
The duration of symptoms had a median value of 
1 month (range 3 days–6 months). The most common 
presenting features were headache, vomiting, seizures, 
blurry vision, diplopia, facial weakness, dysphagia, 
dysarthria, ataxia, dizziness, drowsiness, limb weakness, 
and personality change.
Median Karnofsky performance scores at diagnosis were 
50 (range 20–80).
Radiological features
Based on tumor epicenter, we had 16 (88.9%) tumors 
originating from the pons, 1 (5.6%) tumor originating from 
the cervicomedullary region, and 1 (5.6%) tumor from the 
midbrain.
Tumors arising from the pons showed diffuse pontine 
enlargement that appeared hyperintense on T2 weighted 
images and hypointense on T1‑weighted images. Contrast 
enhancement was seen in 6 patients.
The tumor arising from the cervicomedullary region 
measured 30 mm × 22 mm. The discrete cystic solid 
mass caused obliteration of the fourth ventricle leading to 
hydrocephalus. There was patchy contrast enhancement.
The tumor in the midbrain measured 32.1 mm × 35.4 mm 
on sagittal images. It had a cystic component and a 
contrast‑enhancing solid component. It appeared to 
have a compressive effect on the right internal capsule. 
Table 1: Patient demographic and presentation 
characteristics (n=18)
Characteristic Number
Demographics
Age (years), mean (range) 8.6 (3‑15)
Sex, n (%)
Male 11 (61.1)
Female 7 (38.9)
Presentation
Duration of symptoms (month), median (range) 1 (0.1‑6)
KPS, median (range) 50 (20‑80)
Presenting symptoms, n (%)
Headache 14 (77.8)
Ataxia 14 (77.8)
Diplopia 13 (72.2)
Dysarthria 8 (44.4)
Upper limb weakness 8 (44.4)
Lower limb weakness 8 (44.4)
Vomiting 7 (38.9)
Drowsiness 6 (33.3)
Facial weakness 4 (22.2)
Dysphagia 4 (22.2)
Seizures 3 (16.7)
Decreased vision 2 (11.1)
Dizziness 2 (11.1)
Personality change 2 (11.1)
KPS – Karnofsky performance status
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Subsequent diffusion tensor imaging scan showed 
abnormal hues identified in the posterior limb of the right 
internal capsule, right cortical spinal tract, cortical pontine, 
and cortical bulb tracts.
Classification of tumors
Based on clinical and radiological profiles, we classified 
our tumors into three categories. There were 16 (88.9%) 
cases of DIPG, 1 (5.6%) case of exophytic medullary 
gliomas, and 1 (5.6%) case of midbrain/tectal glioma.
Surgical procedures
6 (33.3%) of patients underwent some surgical intervention. 
The most commonly performed surgical procedure was 
ventriculoperitoneal (VP) shunt which was done in 
5 (22.2%) patients – all belonging to the DIPG classification 
of tumors. 2 (11.1%) patients, with tumors belonging to 
exophytic medullary glioma and midbrain/tectal glioma 
classifications underwent craniotomy and resection. Our 
patient with midbrain/tectal glioma developed subdural 
cerebrospinal fluid (CSF) collection after the surgery. This 
was initially managed with a subdural drain, but due to the 
recurrence of collection, he underwent a subdural peritoneal 
shunt placement.
Pathology
None of our patients underwent a stereotactic biopsy. Our 
patients with tumors belonging to the exophytic medullary 
glioma and midbrain/tectal glioma classifications underwent 
surgical resection. Histopathological evaluation of both 
the resected lesions showed the WHO Grade 1 Pilocytic 
astrocytoma.
Radiotherapy
11 (61.1%) patients underwent radiotherapy. Another 
six patients had also been offered radiation, but due to a 
scarcity of resources and/or overall poor prognosis of the 
disease, they chose not to pursue therapy. Our patient with 
exophytic medullary glioma was not offered radiotherapy 
due to a favorable surgical profile.
Our patients were offered 30 cycles of radiotherapy to add 
up to a total dose of 5400 cGY.
Four patients out of the 11 who received radiotherapy 
did not complete their 30 cycles of therapy. This was due 
to disease progression and death or family decision to 
discontinue treatment.
Survival
The mean OS was 9.7 months (range 1–26 months, median 
8 months). Mean PFS was 6.3 months (range 1–24 months, 
median 3 months).
Diffuse intrinsic pontine glioma
10 (62.5%) out of 16 patients with DIPG had a clinical 
disease progression. 6 (37.5%) had both clinical and 
radiological progression. Mean PFS for patients with DIPG 
was 4.9 months (range 1–18 months, median 3 months). 
All patients with DIPG expired from their disease. The 
mean OS for patients with DIPG was 7.8 months (range 
1–18 months, median 8 months).
Patients who received radiotherapy had a longer PFS as 
opposed to those who did not [Figure 1]. Patients receiving 
radiation had an average PFS of 6 months, whereas patients 
who did not receive radiation had an average PFS of only 
2.4 months. This difference was found to be statistically 
significant (P = 0.03).
Statistically significant survival benefit was found in 
patients who received radiotherapy as opposed to those 
who did not [Figure 2]. The mean OS in DIPG patients 
who received radiation therapy was 9.8 months compared 
to 3.4 months in those who did not (P = 0.01).
Two patients underwent a VP shunt as well as 
radiotherapy (PFS: 3 and 9 months, OS: 3.5 and 12 months) 
and three patients had a VP shunt placement only for 
symptomatic improvement (PFS: 1, 2, and 3 months 
and OS: 1, 2, and 8 months).
Female gender, diagnostic latency >1 month, KPS 
score >60, and nonenhancing pattern were estimated to 
be associated with longer OS. However, this was not 
statistically significant [Table 2].
Diagnostic latency >1 month was found to have a statistically 
significant longer progression free interval [Table 2].
Exophytic medullary glioma
Our patient with exophytic medullary glioma has not 
had a disease progression yet and is currently at PFS of 
24 months.
Midbrain/tectal glioma
Our patient with midbrain/tectal glioma had a radiological 
Figure 1: Kaplan–Meier graph depicting progression-free survival in 
patients with diffuse intrinsic pontine glioma who received radiotherapy 
versus those who did not
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and clinical progression at 12 and 18 months. She is 
currently alive at 26 months after the diagnosis.
Table 3 depicts a summary of our patient’s clinical course 
and outcomes.
Discussion
DIPG formed the majority of tumors in our cohort. These 
tumors, due to their aggressive clinical course, residence in an 
eloquent part of the brain and overall poor prognosis as evident 
from previous literature, as well as our cohort, represent a 
challenge to pediatric neurosurgeons and oncologists.
DIPGs are the most frequently encountered brainstem 
gliomas.[2] Although they can arise in any age group, they 
have a peak onset between 6 and 9 years[3,18] and have 
a median OS of only 9 months.[9,19] There is an equal 
predilection for both sexes.[20] It is estimated that 80% of 
all gliomas in children are DIPG.[20]
Diffuse brainstem gliomas have the classic presentation of 
the neurological triad: cranial neuropathy (cranial nerve 
deficits), long tract signs and ataxia.[4,18,20] A very sensitive 
finding of DIPG is abducens palsy in a young child.[18] 
This occurred in a number of our patients presenting as 
strabismus and diplopia.
DIPG is recognized on MRI by diffuse enlargement 
of the brainstem with or without heterogeneous 
contrast enhancement.[6,13] They appear hyperintense on 
T2‑weighted images and hypointense on T1.[3] These 
features are so characteristic of this pathology that a 
histopathological evaluation is not needed for establishing 
the diagnosis.[3,6,13] The scans of all our DIPG patients 
demonstrated these findings.
None of our patients underwent a stereotactic biopsy 
as we felt confident in our diagnosis based on clinical 
features and characteristic radiology. In the precomputer 
tomography and MRI eras, stereotactic biopsies used to be 
a routine procedure for the histological diagnosis of DIPG. 
This practice was abandoned in the early 1990s due to the 
heterogeneity of these tumors, the associated morbidity of 
these biopsy procedures, the prevalence of poor candidates 
at presentation, limited therapeutic options based on these 
biopsy results and following the advent of the MRI, the 
widespread availability of characteristic imaging findings.[20]
However, it is now agreed that biopsies of these lesions 
are relatively safe due to modern neurosurgical techniques 
and should be considered in the context of clinical trials. 
Currently, the development of targeted therapies has been 
hampered by the lack of understanding regarding tumor 
biology and trials have been conducted based on the 
misconception that DIPG biology is similar to their adult 
counterparts and other pediatric supratentorial malignant 
gliomas.[9] The availability of biopsy material will allow 
for molecular biology analysis, including whole‑genome 
sequencing, thus potentially allowing for the development 
of future therapies.[9]
The current standard of care for DIPG is fractionated 
external beam radiotherapy. Radiotherapy serves only to 
prolong life and does not have a curative purpose as the 
disease is rapidly fatal.[9,18] Our cohort demonstrates a 
statistically significant survival benefit among patients who 
opted for radiotherapy versus those who did not. Radiation 
may be delivered through a conventional radiotherapy 
schedule (6 weeks course with once a day treatment with 
180 cGY per fraction to deliver a total dose of 5400 cGY as 
was done with our patients), hyperfractionated radiotherapy 
schedule (6 weeks course with twice a day treatment with 
117 cGY per fraction to deliver a total dose of 7020 cGY) 
or hypofractionated radiotherapy schedule (2.6 weeks 
Table 2: Overall survival and progression-free survival 
comparisons by log-rank test
OS 
(months)
P PFS 
(months)
P
Gender
Male 6.6 0.36 4.3 0.43
Female 9.8 5.8
Diagnostic latency (month)
<1 5.2 0.19 2.2 0.03
>1 9 6.1
KPS
<60 6.6 0.17 4.0 0.22
>60 11.4 7.5
Contrast
Enhancing 6.5 0.46 3.2 0.19
Nonenhancing 8.6 5.9
Radiotherapy
Yes 9.8 0.01 6.0 0.03
No 3.4 2.4
OS – Overall survival; PFS – Progression‑free survival ; KPS – 
Karnofsky performance status 
Figure 2: Kaplan–Meier graph depicting overall survival in patients with 
diffuse intrinsic pontine glioma who received radiotherapy versus those 
who did not
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course with 300 cGY per fraction to deliver a total dose of 
3900 cGY in 13 fractions).[3,4] A Cochrane review published 
in 2016, comparing different treatment modalities found 
no clear evidence regarding differences in OS and PFS 
between conventional radiotherapy and hypo/hyper 
fractionated radiotherapy.[4] The shorter hypofractionated 
radiotherapy schedule, however, has been found to reduce 
treatment burden while at the same time proving equally 
efficacious.[18]
Currently, there are no proven chemotherapeutic or targeted 
therapy agents that have been shown to improve PFS and 
OS.[18] Radiosensitizers such as carbogen and motexafin 
gadolinium have all found to be ineffective.[18] None of our 
patients received any chemotherapeutic agent.
DIPG due to their diffuse growth pattern and involvement 
of important centers of the brainstem are not amenable to 
surgery. However, five of our DIPG patients had surgical 
intervention in the form of VP shunt placement. This 
was due to the development of obstructive hydrocephalus 
requiring the need for urgent decompression.
On the other hand, focal brainstem gliomas have a subtler 
and more indolent course often presenting with nonspecific 
headache and hydrocephalus.[4,7] We had two such patients 
in our cohort.
Our patient with exophytic medullary glioma presented 
with a KPS score of 80 and a duration of symptoms of 
3.5 months indicating a comparatively slower progression 
of the disease. Exophytic medullary gliomas are low‑grade 
gliomas with a relatively benign clinical course.[3,6] They 
arise from the cervicomedullary junction or from the 
floor of the fourth ventricle and often have a contrast 
enhancing exophytic portion that may be amenable to 
surgical resection.[3,6,13] This was done in our case. There 
may be a need for shunt placement in some patients.[3] 
Prognostically, these patients have a long‑term survival and 
median OS >5 years.[6,13]
The third subgroup, midbrain/tectal gliomas also have 
a relatively benign course. Mean age at diagnosis is 
7–10 years. Given their proximity to the cerebral aqueduct, 
they may often be complicated by hydrocephalus.[6,13] On 
MRI, they appear as a midbrain lesion that is hypointense 
on T1 and hyperintense on T2. They may have marked 
contrast enhancement.[21] Neurosurgical resection is the 
treatment of choice for focal midbrain gliomas with 
the exception of those implicating the tectum.[7] They 
can usually be managed with CSF diversion with shunt 
placement or endoscopic third ventriculostomy and periodic 
radiologic surveillance.[2] Median PFS and OS is beyond 
the follow‑up duration of most studies indicating a good 
prognosis.[3]
Lundar et al. published an institutional series of 15 patients 
with low‑grade midbrain gliomas that were treated with 
surgical resection.[21] Three patients in their series died, one 
of whom had a prolonged survival period of 21 years. One 
patient passed away from acute mesencephalic bleeding 
8 months after the initial surgery. And one patient died 
intraoperatively. Among the 12 surviving patients, stable 
long‑term survival appeared obtainable in at least 9. No 
patient had rapid tumor progression. Based on these 
findings, the authors concluded surgical resection as a 
viable option for focal midbrain gliomas.
Our patient had a KPS at presentation of 80 and a duration 
of symptoms of 4 months, again highlighting the slow 
course of the disease. She underwent a craniotomy and 
resection of her space occupying lesion. Her postoperative 
scans showed an interval reduction of midbrain lesion. 
She was readmitted after 2 weeks as she had developed a 
subdural collection. This was managed with subdural drain 
placement and evacuation of collection. Recurrence of this 
collection after another 10 days led to readmission and 
subsequent management with a subdural peritoneal drain 
placement. She is currently alive at 26 months after the 
initial diagnosis.
Whenever a low‑grade brainstem glioma cannot be totally 
resected but there is modest residual disease with minimal 
neurologic deficits, expectant management with close 
radiologic surveillance is sufficient.[2] However, in cases 
of significant and symptomatic residual disease, adjuvant 
therapy may be offered depending on the efficiency of the 
said therapy of rescue at tumor relapse and provided the risk 
of irreversible injury from additional disease progression 
is greater than the potential toxicity of the adjuvant 
therapies.[2] Our patient with the focal midbrain glioma 
had been recommended to receive adjuvant radiotherapy. 
However, the patient declined the offer. This may have been 
a reason for the tumor progression later encountered.
Limitations
Our study looks at the clinical profiles and outcomes of 
pediatric patients presenting with brainstem glioma that 
received or did not receive any medical intervention at our 
center. However, the small cohort of patients due to the 
rarity of this condition limits the significance of our results. 
It is, therefore, important to be cautious when interpreting 
the findings of our paper. A multi‑institutional study with a 
large number of patients would be able to better elucidate 
the normal progression and outcome of this rare disease.
Conclusion
DIPGs in the pediatric population have a poor prognosis. 
Radiotherapy serves to increase survival time but is not 
curative. In comparison focal low‑grade gliomas in the 
medulla and midbrain are amenable to surgical intervention 
and generally have a good prognosis with long OS.
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